K Pharma,Inc. (JP:4896)
:4896
Top Page
K Pharma,Inc.
(4896)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥716.00
▲(9.98% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance (zero revenue in 2024–2025, sizable losses, ongoing cash burn, and rising leverage with declining equity). Technicals are mixed/neutral with an oversold signal, providing only limited support, while valuation remains unattractive due to negative earnings and no dividend.
Positive Factors
Prior revenue and profitable year (2023)
The company reported revenue and net income in 2023 (¥1.0B revenue, ¥260M net income), demonstrating prior commercial or milestone capability. This historical revenue shows the business can generate cash and commercialize outputs, reducing pure pre-revenue execution risk over time and providing a precedent for potential revenue recovery if programs advance or partnerships occur.
Negative Factors
Zero revenue in 2024–2025
The company reported zero revenue in 2024–2025 and shifted from profitable 2023 to large operating and net losses. Persistent absence of revenue removes margin generation and forces reliance on external financing or partnerships to fund development, raising execution risk and making medium-term sustainability contingent on successful funding or commercial milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Prior revenue and profitable year (2023)
The company reported revenue and net income in 2023 (¥1.0B revenue, ¥260M net income), demonstrating prior commercial or milestone capability. This historical revenue shows the business can generate cash and commercialize outputs, reducing pure pre-revenue execution risk over time and providing a precedent for potential revenue recovery if programs advance or partnerships occur.
Read all positive factors
K Pharma,Inc. (4896) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.61B
Dividend YieldN/A
Average Volume (3M)48.08K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-26.83
Shares Outstanding11,622,600
10 Day Avg. Volume47,520
30 Day Avg. Volume48,080
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-8.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
K Pharma,Inc. Business Overview & Revenue Model
Company Description
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technol...
K Pharma,Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.00B | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 910.00M | 0.00 | -6.80M |
| EBITDA | -916.06M | -844.10M | 366.06M | -390.53M | -222.31M |
| Net Income | -993.23M | -846.46M | 260.33M | -392.43M | -228.72M |
Balance Sheet | |||||
| Total Assets | 2.94B | 2.35B | 3.31B | 1.37B | 205.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.79B | 2.27B | 3.27B | 1.34B | 188.78M |
| Total Debt | 1.50B | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.67B | 94.76M | 209.13M | 38.30M | 26.88M |
| Stockholders Equity | 1.27B | 2.26B | 3.10B | 1.34B | 178.89M |
Cash Flow | |||||
| Free Cash Flow | -929.19M | -998.21M | 444.62M | -393.44M | -196.32M |
| Operating Cash Flow | -918.00M | -983.72M | 454.43M | -363.48M | -196.32M |
| Investing Cash Flow | -54.68M | -14.49M | -11.10M | -32.74M | -250.00K |
| Financing Cash Flow | 1.50B | 0.00 | 1.49B | 1.54B | 368.20M |
K Pharma,Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.86B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
56 Neutral | ¥7.72B | 33.49 | ― | ― | 2.99% | -52.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥9.17B | -2.75 | ― | ― | 1221.43% | 30.54% | |
49 Neutral | ¥11.08B | -8.14 | ― | ― | -42.49% | -2.37% | |
47 Neutral | ¥7.48B | -7.39 | ― | ― | 25.28% | 39.15% | |
44 Neutral | ¥8.61B | -7.71 | ― | ― | ― | ― |
* Healthcare Sector Average
JP:4896
K Pharma,Inc.
741.00
177.00
31.38%
JP:4583
Chiome Bioscience Inc.
103.00
-25.00
-19.53%
JP:4594
BrightPath Biotherapeutics Co.Ltd.
66.00
30.00
83.33%
JP:4880
CellSource Co., Ltd.
396.00
-212.89
-34.96%
JP:7096
StemCell Institute
753.00
-525.00
-41.08%
JP:7776
CellSeed Inc.
285.00
-182.00
-38.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.